Trial reportArthritis research & therapy2026
No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.
Trial report in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecukinumab is an interleukin (IL)-17 inhibitor approved to treat patients with axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Treatment recommendations highlight the importance of individualized treatment of patients with axSpA according to symptoms, extra-musculoskeletal manifestations, and comorbidities. The objective of this post hoc analysis was to compare clinical responses to secukinumab treatment through Week 16 between younger and older patients with r-axSpA and nr-axSpA from six placebo-controlled phase 3 clinical studies.
methodsThis post hoc analysis evaluated data pooled from 1427 patients with axSpA from the MEASURE 1-5 trials (NCT01358175, NCT01649375, NCT02008916, NCT02159053, and NCT02896127) and the PREVENT trial (NCT02696031). All patients were randomized to secukinumab 150 mg, 300 mg, or placebo through Week 16. Patient subgroups were defined based on median age at baseline (18 to < 40 years vs. ≥ 40 years). Treatment effect (secukinumab 150/300 mg vs. placebo) within each age subgroup and the difference in treatment effect between younger vs. older age subgroups were assessed.
resultsSecukinumab treatment demonstrated clinical efficacy and improvements in patient-reported outcomes vs. placebo at Week 16 in patients with r-axSpA or nr-axSpA irrespective of age. No difference in treatment effect of ASAS20, ASAS40, or ASDAS response was observed between younger vs. older patients with r-axSpA or nr-axSpA (all P>.05). Among patients with r-axSpA, younger patients experienced a larger treatment effect of secukinumab on SF-36 than older patients (difference in least-squares mean [LSM]: 2.2; P < .05). Among patients with nr-axSpA, younger patients experienced a larger treatment effect of secukinumab on the Berlin SIJ total edema score (difference in LSM: - 1.2; P < .05) and Total ASspi-MRI-a score (LSM, - 0.4; P<.05).
conclusionClinical efficacy of secukinumab vs. placebo at Week 16 was generally similar between older and younger patients with either r-axSpA or nr-axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.